<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870334</url>
  </required_header>
  <id_info>
    <org_study_id>BT-11-202</org_study_id>
    <nct_id>NCT03870334</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Landos Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Landos Biopharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter&#xD;
      induction study. The purpose of this study is to evaluate the efficacy and safety of oral&#xD;
      BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 100&#xD;
      sites will participate from Europe and the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 150 subjects will be randomized in a 1:1 ratio, in a centralized manner, to&#xD;
      receive BT 11 1000 mg or placebo. Each of the treatment arms will comprise 75 subjects. The&#xD;
      randomization will be stratified by prior exposure to biologic therapy for CD (yes/no;&#xD;
      exposed population limited to 50% of total sample) and corticosteroid use at baseline&#xD;
      (yes/no).&#xD;
&#xD;
      The study will consist of a 28-day screening period, a 12-week induction period, an 18-week&#xD;
      maintenance period, and a 2-week posttreatment safety follow-up period.&#xD;
&#xD;
      Subjects who are nonresponders at Week 12, or who lose response during the maintenance&#xD;
      period, or who complete the Week 30 study will be eligible for a separate open-label&#xD;
      extension (OLE) study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 100 sites will participate from Europe and the USA. A total of 150 subjects with moderate to severe CD (CDAI Score 220-450 and a Simplified Endoscopic Index of Severity of Crohn's Disease (SES-CD) SCORED ≥ 6 (≥ 4 for isolated ileitis) will be randomized in a 1:1 ratio to receive BT-11 1,000 mg or placebo. Each of the treatment arms will comprise 75 subjects. The randomization will be stratified by prior exposure to biologic therapy for CD (yes/no) and corticosteroid use at baseline (yes/no). The study consists of a 28-day screening period, a 12-week induction phase, and a 2-week post-treatment safety follow-up period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical remission defined by CDAI score &lt;150.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>12 weeks</time_frame>
    <description>CDAI reduction from baseline ≥ 100 points or CDAI &lt; 150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>SES-CD OF 0-2 or SES-CD ≤ 4, a ≥2-point improvement over baseline, and no sub-score &gt; 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Geboes score &lt; 2B.1 (with absence of neutrophils in lamina propria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of subjects achieving clinical remission defined as 50% reduction from baseline in SES-CD score at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>BT-11 1,000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT-11 1,000 mg</intervention_name>
    <description>Subjects will be randomized to receive BT-11 1,000 mg once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (BT-11, or placebo).</description>
    <arm_group_label>BT-11 1,000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized to receive Placebo once daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (BT-11, or placebo).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;&#xD;
&#xD;
          2. Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD&#xD;
             scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);&#xD;
&#xD;
          3. Prior biologic must have stopped at least 8 weeks before study (or within 4 weeks&#xD;
             prior to randomization, if no detectable drug levels by validated or commercial assay)&#xD;
             and previous biologic treatment failure is limited to 1 class of biologic (if&#xD;
             applicable);&#xD;
&#xD;
          4. 5 aminosalicylates (max 4.8 g/day) and oral corticosteroids (max 20 mg/day prednisone&#xD;
             or equivalent) must be stable for the duration of the 12-week induction period.&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          1. Ulcerative colitis;&#xD;
&#xD;
          2. Imminent risk of ileocolectomy; symptomatic bowel stricture, ostomy or ileoanal pouch,&#xD;
             stenoses, or short gut syndrome;&#xD;
&#xD;
          3. Recent (within 2 months) abscess, unless drained and treated at least 6 weeks before&#xD;
             randomization;&#xD;
&#xD;
          4. History of bowel resection or diversion within 3 months prior to screening;&#xD;
&#xD;
          5. Use of apheresis ≤ 2 weeks prior to screening; treatment with an immunosuppressant&#xD;
             within 25 days prior to randomization;&#xD;
&#xD;
          6. Known current bacterial or parasitic pathogenic enteric infection; live virus&#xD;
             vaccination within 12 weeks of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti Chauhan</last_name>
    <role>Study Director</role>
    <affiliation>Landos Biopharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Bassaganya Riera</last_name>
    <phone>5402182232</phone>
    <email>jbr@landosbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jyoti Chauhan</last_name>
    <email>jyoti@landosbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Avant Clinical Research - Huntsville</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smita Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassel Kisso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allameh Medical Corp</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Allamehzadeh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.H.S Health LLC</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syeed Lateef, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inti Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCP Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiraz Farooq, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avant Clinical Research - Crowley</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satinder Saini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodholme Gastroenterology Associates</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenolisa Onwueme, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, LLC</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Kaufman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Digestive Diseases PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Goldstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmington Health</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Webster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald McNeil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Stokesberry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GI Clinical Research Enterprise</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schwartz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lonestar Gastroenterology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Preiksaitis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Medika Ruse OOD</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Venceslav Draganov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan Kulinski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical center-1-Sevlievo EOOD, Gastroenterology cabinet</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Temenuzhka Berova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment, Sv. Ivan Rilski &quot;EAD, Gastroenterology clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoia Spassova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DC-MED</name>
      <address>
        <city>Swidnica</city>
        <state>Dolnoslaskie</state>
        <zip>58-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Witold Marczynski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Lecznej</name>
      <address>
        <city>Leczna</city>
        <state>Lubelskie</state>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Wolanski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allmedica</name>
      <address>
        <city>Nowy Targ</city>
        <state>Malopolska</state>
        <zip>34-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikolaj Krzyzanowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Kierkus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyk</name>
      <address>
        <city>Rzeszów</city>
        <state>Podkarpackie</state>
        <zip>35-326</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Filip, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sopmed</name>
      <address>
        <city>Sopot</city>
        <state>Pomorskie</state>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Kleczkowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Solumed</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-259</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Karczewski, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

